Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 2/20 | 0.66 |
| ▸ | ABCG2 | Q9UNQ0 | 5/20 | 0.61 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | RAD52 | P43351 | 1/20 | 0.57 |
| ▸ | CDC7 | O00311 | 1/20 | 0.56 |
| ▸ | KDR | P35968 | 2/20 | 0.55 |
| ▸ | EGFR | P00533 | 3/20 | 0.52 |
| ▸ | PAK4 | O96013 | 2/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.49 |
| ▸ | CCR4 | P51679 | 1/20 | 0.48 |
| ▸ | IGF1R | P08069 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3586555 | 0.93 | RET (0.65) | RETABCG2SLC2A1TP53MAPT | |
| SCHEMBL3578638 | 0.92 | RET (0.64) | RETABCG2SLC2A1TP53MAPT | |
| SCHEMBL13316009 | 0.92 | RET (0.66) | RETABCG2SLC2A1KDREGFR | |
| SCHEMBL3579006 | 0.92 | RET (0.66) | RETABCG2SLC2A1TP53MAPT | |
| SCHEMBL3100763 | 0.91 | RET (0.63) | RETABCG2SLC2A1TP53MAPT | |
| SCHEMBL13154700 | 0.91 | RET (0.65) | RETABCG2SLC2A1TP53MAPT | |
| SCHEMBL3577677 | 0.90 | ABCG2 (0.63) | RETABCG2SLC2A1TP53MAPT | |
| SCHEMBL3582018 | 0.90 | RET (0.62) | RETABCG2SLC2A1TP53MAPT | |
| SCHEMBL3581389 | 0.89 | RET (0.61) | RETABCG2SLC2A1TP53MAPT | |
| SCHEMBL3584700 | 0.89 | RET (0.61) | RETABCG2SLC2A1TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100249159-A1 | RHO-KINASE INHIBITORS | NAGARATHNAM DHANAPALAN | 2010-09-30 | — | — | US | disclosed |
| US-20100249159-A1 | RHO-KINASE INHIBITORS | NAGARATHNAM DHANAPALAN | 2010-09-30 | — | — | US | disclosed |
| US-20100137324-A1 | RHO-KINASE INHIBITORS | NAGARATHNAM DHANAPHALAN | 2010-06-03 | — | — | US | disclosed |
| US-20100137324-A1 | RHO-KINASE INHIBITORS | NAGARATHNAM DHANAPHALAN | 2010-06-03 | — | — | US | disclosed |
| US-20100125139-A1 | PROCESS FOR PREPARING QUINAZOLINE RHO-KINASE INHIBITORS AND INTERMEDIATES THEREOF | BANKSTON DONALD | 2010-05-20 | — | — | US | disclosed |
| US-20100125139-A1 | PROCESS FOR PREPARING QUINAZOLINE RHO-KINASE INHIBITORS AND INTERMEDIATES THEREOF | BANKSTON DONALD | 2010-05-20 | — | — | US | disclosed |
| US-7645878-B2 | Reacting an aniline derivative with an acylchloride to form an intermeidate, cyclizing the intermediate, replacing hydroxy group with a leaving group (chloride), racting the product with an amino-heterocyclic compound | BAYER HEALTHCARE LLC (US) | 2010-01-12 | — | — | US | disclosed |
| US-7645878-B2 | Reacting an aniline derivative with an acylchloride to form an intermeidate, cyclizing the intermediate, replacing hydroxy group with a leaving group (chloride), racting the product with an amino-heterocyclic compound | BAYER HEALTHCARE LLC (US) | 2010-01-12 | — | — | US | disclosed |
| EP-1953152-A1 | Process for preparing quinazoline RHO-kinase inhibitors and intermediates thereof | Bayer Corporation (US) | 2008-08-06 | — | — | EP | disclosed |
| EP-1370552-B1 | RHO-KINASE INHIBITORS | BAYER PHARMACEUTICALS CORP (US) | 2007-02-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137324-A1 | RHO-KINASE INHIBITORS | CIT, ROCK1, ROCK2 | RET 801/4885ABCG2 3107/4885SLC2A1 4666/4885 |
| US-20100249159-A1 | RHO-KINASE INHIBITORS | CIT, ROCK1, ROCK2 | RET 801/4885ABCG2 3107/4885SLC2A1 4666/4885 |
| US-20100125139-A1 | PROCESS FOR PREPARING QUINAZOLINE RHO-KINASE INHIBITORS AND INTERMEDIATES THEREOF | ROCK1, ROCK2, CIT | RET 1193/4885ABCG2 1652/4885SLC2A1 4608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.